

Datasheet for ABIN2018242 CCL22 Protein



Overview

Quantity:	10 µg
Target:	CCL22
Origin:	Rat
Source:	Escherichia coli (E. coli)
Protein Type:	Recombinant
Biological Activity:	Active
Product Details	
Sequence:	GPYGANVEDS ICCQDYIRHP LPPRFVKEFY WTSKSCRKPG VVLITIKNRD ICADPRMLWV KKILHKLA
Sequence: Characteristics:	
	KKILHKLA Fully biologically active when compared to standard. The biologically active determined by a
Characteristics:	KKILHKLA Fully biologically active when compared to standard. The biologically active determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration range of 10-100 ng/mL.
Characteristics: Purity:	KKILHKLA Fully biologically active when compared to standard. The biologically active determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration range of 10-100 ng/mL. > 96 % by SDS-PAGE and HPLC analyses.

Target Details

Target:	CCL22
Alternative Name:	MDC/CCL22 (CCL22 Products)
Background:	Macrophage-Derived Chemokine/CCL22 (MDC) is a CC chemokine that is produced in B cells, macrophages, monocyte-derived dendritic cells, activated NK cells and CD4 T cells. It signals

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/2 | Product datasheet for ABIN2018242 | 07/26/2024 | Copyright antibodies-online. All rights reserved.

Target Details

	through the CCR4 receptor. MDC chemoattracts monocytes, dendritic cells and NK cells and
	exerts HIV suppressive activity.
	Synonyms: C-C motif chemokine 22, Small-inducible cytokine A22, Macrophage-derived
	chemokine, MDC(1-69), Stimulated T-cell chemotactic protein 1, CC chemokine STCP-1, CCL22,
	MDC, SCYA22, ABCD-1, DC/B-CK, MGC34554, A-152E5.1, CC chemokine ABCD-1, Activated B
	and dendritic cell-derived, DCBCK.
Molecular Weight:	7.9 kDa, a single, non-glycosylated polypeptide chain containing 68 amino acids.
Application Details	
Restrictions:	For Research Use only
Handling	
Format:	Lyophilized
Reconstitution:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
	bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a
	concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots
	and stored at \leq -20 °C. Further dilutions should be made in appropriate buffered solutions.
Buffer:	Lyophilized from a 0.2 μm filtered concentrated solution in 2 x PBS, pH 7.4.
Handling Advice:	Avoid repeated freeze/thaw cycles.
Storage:	4 °C/-20 °C
Storage Comment:	This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term
	storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week
	at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots
	and store at -20 °C to -70 °C.